Previous 10 | Next 10 |
Amylyx - founded by two Brown University students in 2013 - has developed a therapy for Amyotrophic Lateral Sclerosis, AMX-0035. Its Phase 2 CENTAUR trial data suggested the drug showed benefit on both function and survival - the first ALS drug to do so. ALS is an area of high unm...
Amylyx Pharmaceuticals (NASDAQ:AMLX) stock closed nearly 25% higher on Tuesday, a day after jumping as much as 11.9% on getting Health Canada's conditional approval for its oral medication for neurodegenerative disease amyotrophic lateral sclerosis (ALS). Citi researc...
Cambridge, Massachusetts-based biotech Amylyx Pharmaceuticals (NASDAQ:AMLX) announced on Monday that Health Canada approved Albrioza, its oral medication for amyotrophic lateral sclerosis (ALS) under conditions. The approval marks the first global regulatory approval for the company, and Albr...
Health Canada decision signifies the first global regulatory approval for Amylyx and the first new therapy for ALS approved in Canada since 2018 ALBRIOZA (also known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone ther...
Gainers: Bluejay Diagnostics BJDX +29%. DBV Technologies DBVT +12%. Arcellx (ACLX) +10%. Immix Biopharma (IMMX) +10%. AbCellera Biologics (ABCL) +8%. Losers: Precision BioSciences (DTIL) -10%. Blueprint Medicines (BPMC) -9%. Hutchmed (China) (HCM)&...
Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The number of positions decreased from 107 to 56. Viking Global increased Amazon.com, Fortive, and International Flavors & Fragrances while dropping Humana, Coupa Software, and Twilio. The top thre...
Gainers: Turning Point Therapeutics (TPTX) +117%. Energy Focus (EFOI) +40%. Galecto (GLTO) +25%. Adaptimmune (ADAP) +22%. Amylyx Pharmaceuticals (AMLX) +22%. AudioEye (AEYE) +20%. Sprague Resources LP (SRLP) +20%. Global Cord Blood (CO) +18%. GreenBox (GBOX) +17%. Kopin (KOPN) +15%. Losers: N...
Dropbox (NASDAQ:DBX) received attention in Friday's intraday action, rising on takeover speculation. The list of midday gainers also included Okta (OKTA), which rallied in the wake of a stronger-than-expected quarterly report. Elsewhere in the market, Amylyx (AMLX) soared more than 20% on opt...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amylyx Pharmaceuticals (NASDAQ: AMLX ) is rising on FDA news. The FDA is extending its review period of an NDA. This has holders of AMLX stock hoping for the drug’s approval. Source: Shutterstock ...
Gainers: Turning Point Therapeutics (TPTX) +116%. Amylyx Pharmaceuticals (AMLX) +27%. Yumanity Therapeutics (YMTX) +11%. Amarin (AMRN) +9%. Galecto (GLTO) +8%. Losers: Novavax (NVAX) -13%. Rallybio (RLYB) -13%. Invitae (NVTA) -9%. Spruce Bioscience...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...